Cedra Appoints New CEO

Thursday, May 13, 2010 07:43 AM

Cedra, a division of Worldwide Clinical Trials (WCT), appointed Anthony Busa, Jr., as its new permanent CEO, replacing Cedra founder David Garcia. Thomas Wardle, chief operating officer of WCT, has served as interim CEO since Garcia stepped down earlier this year.

Busa has 34 years of experience within the pharmaceutical and medical devices industries and has held senior management positions at McClintic Busa Group (a clinical trials consulting firm that Busa co-founded in 1998), Dgd Research, Esoterix, Medsites and Covance.

“[Busa] has a thorough understanding of how this business and industry functions,” Wardle said. “He will be a great asset to our team in terms of growth and management.”   

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs